{"name":"Harbour BioMed (Guangzhou) Co. Ltd.","slug":"harbour-biomed-guangzhou-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HBM4003 and pembrolizumab","genericName":"HBM4003 and pembrolizumab","slug":"hbm4003-and-pembrolizumab","indication":"Other","status":"phase_1"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HBM9036 0.25% Ophthalmic Solution","genericName":"HBM9036 0.25% Ophthalmic Solution","slug":"hbm9036-0-25-ophthalmic-solution","indication":"Dry eye disease","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"HBM9161 Injection (680mg)","genericName":"HBM9161 Injection (680mg)","slug":"hbm9161-injection-680mg","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"HBM4003 and pembrolizumab","genericName":"HBM4003 and pembrolizumab","slug":"hbm4003-and-pembrolizumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HBM9036 0.25% Ophthalmic Solution","genericName":"HBM9036 0.25% Ophthalmic Solution","slug":"hbm9036-0-25-ophthalmic-solution","phase":"phase_3","mechanism":"HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye.","indications":["Dry eye disease"],"catalyst":""},{"name":"HBM9161 Injection (680mg)","genericName":"HBM9161 Injection (680mg)","slug":"hbm9161-injection-680mg","phase":"phase_3","mechanism":"HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQZVhybmRfemM2THp1X1J0T05rMlJBTFpZUGl1LV8wTWVISm15ZEx6cEF6Z2c4eERTZ2YzUjRnRjVJMHkyQU1uZWdYQ1JUV29LdEZ6MU82a2tQQ19Yd1g5emdBOHNfTS13bGQ2SnhudFBPVTZXNnZNYWdfb3hEWUNRbjNMdEplSHNPRzN1U1BjbWppVXRJSWgzb0FGQzFfVElT?oc=5","date":"2025-08-27","type":"pipeline","source":"PR Newswire","summary":"Harbour BioMed Reports 2025 Interim Results - PR Newswire","headline":"Harbour BioMed Reports 2025 Interim Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQaHRUMHlDaFFEanVRR3I1cFRuRFZYR3B3RW1Qdkt2cnpMTEJqQ1NnVUlDQmpQd0JsTTk3cmFmcVY2OEJSX2pXcmZUV2taODdsZGJKc2ZmMnhIYy1LekROaGpGWG5yaGpzbzNhRWx1ZTdYVllYZUpRalhZc2llSDNMbndzZm5FUlZiaDhYS2NaU05JWkFCVmE4TVhUbWw0YkdFMkxRNkxIdWg1UXYyNXVFT2s4UjFLM0ZXRFNVc0xwRUJ3X2Fzc0h2dVdYNHJ5UG55VlJRXy16Ym1UbmVkSnYzM0pGVEtxZWNIOUdwRjRRWFBsRTRN?oc=5","date":"2025-05-22","type":"regulatory","source":"PR Newswire","summary":"Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight - PR Newswire","headline":"Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPTWtuSHhQMHhNT003LVhkUXdsTlNQcnV2TnlmMGJhUUNiYzVSZXJEOE5ueWNjUF9oNGtNMWVIUVd5b0lzQmZRelhBamZfVE9xTzJsX2FPVnNOZ29SX3M1MFEtMEZDYXQ4aDZpVzBQLW1NT3NxT3g3UnF1NHpxSDFRcXkwYlgxTGZVRTZYOHRPUVhFUHZjaGxWZktYYVJOcFlkcmRhWnZrTmgwSWRGTzNwak1CMmRycndOWlFSMHY3VERiREhTeW5lLWpOX0R3bHlSM3c?oc=5","date":"2025-03-21","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing - AstraZeneca","headline":"AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}